Pan-Cancer Genomic Analysis Reveals FOXA1 Amplification Is Associated With Adverse Outcomes in Non-Small Cell Lung, Prostate, and Breast Cancers

FOXA1 alterations were characterized across >87,000 samples from over 30 cancer types for primary and metastatic tumors alongside patient characteristics and clinical outcomes.